Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Revenio Group OyjREVXF 79 Net-Net Working Capital is $0.41 as of Mar. 2026. GuruFocus rates REVXF with a GF Score™ of 79/100 and a GF Value™ of $36.37. The stock has 2 warning signs investors should review. Among 417 Medical Devices & Instruments companies, Revenio Group Oyj ranks worse than 89.93% on this metric.
In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. This is a conservative way of estimating the company's value.
Revenio Group Oyj's Net-Net Working Capital for the quarter that ended in Mar. 2026 was $0.41.
The industry rank for Revenio Group Oyj's Net-Net Working Capital or its related term are showing as below:
REVXF's Price-to-Net-Net-Working-Capital is ranked worse than 89.93% of 417
companies
in the Medical Devices & Instruments industry
Industry Median: 7.01
vs REVXF: 40.02
Revenio Group Oyj (OTCPK:REVXF) Net-Net Working Capital Explanation
One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.
Benjamin Graham looked for companies whose market values were less than two-thirds of their net-net value. They are collected under our Net-Net screener.
Revenio Group Oyj Net-Net Working Capital Related Terms
Revenio Group Oyj Net-Net Working Capital Historical Data
* Premium members only.
The historical data trend for Revenio Group Oyj's Net-Net Working Capital can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
REVXF vs ABT, SYK, MDT: Net-Net Working Capital Comparison
For the Medical Devices subindustry, Revenio Group Oyj's Price-to-Net-Net-Working-Capital, along with its competitors' market caps and Price-to-Net-Net-Working-Capital data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Revenio Group Oyj Price-to-Net-Net-Working-Capital vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Revenio Group Oyj's Price-to-Net-Net-Working-Capital distribution charts can be found below:
* The bar in red indicates where Revenio Group Oyj's Price-to-Net-Net-Working-Capital falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full.
In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.
This is a conservative way of estimating the company's value.
What does a Net-Net Working Capital of $0.41 mean?
Revenio Group Oyj (REVXF) has a Net-Net Working Capital of $0.41 as of Mar. 2026. Ben Graham defined net-net working capital as the per-share sum of cash, 75% of receivables and 50% of inventory less total liabilities. View historical data on Revenio Group Oyj According to the industry distribution chart, Revenio Group Oyj ranks #375 out of 417 companies in the Medical Devices & Instruments industry, placing it in the top 89.9%.
Is Revenio Group Oyj's Net-Net Working Capital too high?
Revenio Group Oyj's current Net-Net Working Capital is $0.41. The Medical Devices & Instruments industry median Net-Net Working Capital is 7.01. Revenio Group Oyj's value of $0.41 is 94.2% below this industry median. Based on the distribution chart, Revenio Group Oyj ranks #375 out of 417 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Revenio Group Oyj has a GF Score™ of 79/100, reflecting its overall financial health beyond just this single metric.
How does Revenio Group Oyj's Net-Net Working Capital compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Revenio Group Oyj ranks #375 out of 417 companies for Net-Net Working Capital. This places Revenio Group Oyj in the lower half of its industry. The industry median Net-Net Working Capital is 7.01. Revenio Group Oyj's value of $0.41 is 94.2% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net-Net Working Capital for a Medical Devices & Instruments company?
The median Net-Net Working Capital among Medical Devices & Instruments companies is 7.01, based on 417 companies in the industry. Companies in the top quartile (top 25%) have a Net-Net Working Capital significantly above this median, while those in the bottom quartile fall well below. However, Net-Net Working Capital should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Revenio Group Oyj's current Net-Net Working Capital of $0.41 is 94.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net-Net Working Capital mean?
A high Net-Net Working Capital can signal that a stock is expensive relative to its fundamentals. Ben Graham defined net-net working capital as the per-share sum of cash, 75% of receivables and 50% of inventory less total liabilities. View historical data on Revenio Group Oyj For the Medical Devices & Instruments industry, the median Net-Net Working Capital is 7.01 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Revenio Group Oyj's current Net-Net Working Capital is $0.41. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Revenio Group Oyj stock overvalued right now?
Revenio Group Oyj (REVXF) has a current Net-Net Working Capital of $0.41. The stock's GF Value™ is $36.37, compared to a current price of $16.41 — trading 54.9% below its estimated fair value. The current Net-Net Working Capital is $0.41 and 94.2% below the Medical Devices & Instruments industry median of 7.01. Revenio Group Oyj's overall GF Score™ is 79/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net-Net Working Capital calculated?
Net-Net Working Capital is calculated from a company's financial statements. For Revenio Group Oyj (REVXF), the current Net-Net Working Capital is $0.41 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Revenio Group Oyj (REVXF) Overvalued in 2026?
Based on GuruFocus' analysis, Revenio Group Oyj stock appears to be undervalued.
The current stock price of $16.41 is trading 54.9% below its estimated GF Value™ of $36.37.
Key valuation signals for REVXF:
Net-Net Working Capital: $0.41
GF Value™: $36.37 vs. price of $16.41 (54.9% below fair value)
Industry Position: 94.2% below the Medical Devices & Instruments median (#375 of 417)
No single metric tells the full story. See the REVXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Revenio Group Oyj is a Finnish health technology company. It develops and commercializes effective, easy-to-use health tech-related screening devices for detecting diseases of public health significance. Its ophthalmic diagnostic solutions include intraocular pressure (IOP) measurement devices (tonometers), and perimeter and fundus imaging devices under the iCare brand. Its eye care software platform, Oculo, offers clinical communication, telehealth, remote patient monitoring, and data analytics capabilities. The company generates the majority of its revenue from the United States.
79GF Score
Get the complete analysis for REVXF
Net-Net Working Capital is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
REVXF has been successfully added to your 
